Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716806 · ClinicalTrials.gov registry record · Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
A Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT01716806 is a Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease that has completed, run by Seagen. The registered enrollment target is 131 participants, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01716806, a Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG brentuximab vedotin
- DRUG bendamustine
- DRUG dacarbazine
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Cancer Center / University of Arizona - Tucson
California
- Providence St Joseph Medical Center - Burbank
- City of Hope National Medical Center - Duarte
- Wilshire Oncology Medical Group Inc. - Pomona
Alabama
- University of Alabama at Birmingham - Birmingham
- University of South Alabama - Mitchell Cancer Institute - Mobile
Georgia
- IACT Health - Columbus
- Georgia Cancer Specialists / Northside Hospital Cancer Institute - Sandy Springs
Illinois
- Rush University Medical Center - Chicago
- Illinois Cancer Specialists / Advocate Lutheran General Hospital - Niles
Alaska
- Alaska Urological Institute - Anchorage
Arkansas
- Highlands Oncology Group - Springdale
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716806
The ClinicalTrials.gov registry entry for NCT01716806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (28% higher). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.
NCT01716806 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01716806 about?
NCT01716806 is a clinical study titled "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)". This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study ...
What is the current status of trial NCT01716806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2012-10-31. Estimated completion is 2023-09-12.
What conditions does trial NCT01716806 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Hodgkin Disease.
What interventions are being tested in trial NCT01716806?
The interventions under investigation include: nivolumab (DRUG), brentuximab vedotin (DRUG), bendamustine (DRUG), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT01716806?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01716806 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.